In addition FIGO stage (p<0.001) and response to chemotherapy (p<0.001) also remained independent predictors of patient survival suggesting that HMGB1 may be a useful independent prognostic marker in ovarian cancer. This evidence concerns the gene HMGB1 and ovarian carcinoma.